A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996

Clinical Trial

J M Gallo et al. Cancer Res. 1997.

. 1997 Jul 15;57(14):3063-5.

No abstract available

Comment on

Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dörken B, Herrmann F, Gürtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D. Lübbe AS, et al. Cancer Res. 1996 Oct 15;56(20):4686-93. Cancer Res. 1996. PMID: 8840985 Clinical Trial.
Preclinical experiences with magnetic drug targeting: tolerance and efficacy.
Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D. Lübbe AS, et al. Cancer Res. 1996 Oct 15;56(20):4694-701. Cancer Res. 1996. PMID: 8840986